Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage

Jing Li, Charles T. Stier, Praveen N. Chander, Vijay L. Manthati, J R Falck, Mairéad A. Carroll

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Kidney damage is markedly accelerated by high-salt (HS) intake in stroke-prone spontaneously hypertensive rats (SHRSP). Epoxyeicosatrienoic acids (EETs) are epoxygenase products of arachidonic acid which possess vasodepressor, natriuretic, and anti-inflammatory activities. We examined whether up-regulation (clofibrate) or inhibition [N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH)] of epoxygenase would alter systolic blood pressure (SBP) and/or renal pathology in SHRSP on HS intake (1% NaCl drinking solution). Three weeks of treatment with clofibrate induced renal cortical protein expression of CYP2C23 and increased urinary excretion of EETs compared with vehicle-treated SHRSP. SBP and urinary protein excretion (UPE) were significantly lowered with clofibrate treatment. Kidneys from vehicle-treated SHRSP, which were on HS intake for 3 weeks, demonstrated focal lesions of vascular fibrinoid degeneration, which were markedly attenuated with clofibrate treatment. In contrast, 2 weeks of treatment with the selective epoxygenase inhibitor, MS-PPOH, increased UPE without significantly altering neither urinary EET levels nor SBP. Kidneys from vehicle-treated SHRSP, which were on HS intake for 11 days, demonstrated occasional mild damage whereas kidneys from MS-PPOH-treated rats exhibited widespread malignant nephrosclerosis. These results suggest that pharmacological manipulation of epoxygenase results in divergent effects on renal damage and that interventions to increase EET levels may provide therapeutic strategies for treating salt-sensitive hypertension and renal damage.

Original languageEnglish (US)
Article numberArticle 187
JournalFrontiers in Pharmacology
Volume5 AUG
DOIs
StatePublished - 2014

Fingerprint

Clofibrate
Pharmacology
Kidney
Blood Pressure
Salts
Nephrosclerosis
Proteins
Renal Hypertension
Inbred SHR Rats
arachidonate epoxygenase
Drinking
Blood Vessels
Anti-Inflammatory Agents
Up-Regulation
Stroke
Pathology
Acids
N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide

Keywords

  • Clofibrate
  • Epoxyeicosatrienoic acids
  • Epoxygenase inhibition
  • High-salt intake
  • Proteinuria
  • Renal damage
  • SHRSP

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage. / Li, Jing; Stier, Charles T.; Chander, Praveen N.; Manthati, Vijay L.; Falck, J R; Carroll, Mairéad A.

In: Frontiers in Pharmacology, Vol. 5 AUG, Article 187, 2014.

Research output: Contribution to journalArticle

Li, Jing ; Stier, Charles T. ; Chander, Praveen N. ; Manthati, Vijay L. ; Falck, J R ; Carroll, Mairéad A. / Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage. In: Frontiers in Pharmacology. 2014 ; Vol. 5 AUG.
@article{547ccd5cf54848a0a982a7eb482d7120,
title = "Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage",
abstract = "Kidney damage is markedly accelerated by high-salt (HS) intake in stroke-prone spontaneously hypertensive rats (SHRSP). Epoxyeicosatrienoic acids (EETs) are epoxygenase products of arachidonic acid which possess vasodepressor, natriuretic, and anti-inflammatory activities. We examined whether up-regulation (clofibrate) or inhibition [N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH)] of epoxygenase would alter systolic blood pressure (SBP) and/or renal pathology in SHRSP on HS intake (1{\%} NaCl drinking solution). Three weeks of treatment with clofibrate induced renal cortical protein expression of CYP2C23 and increased urinary excretion of EETs compared with vehicle-treated SHRSP. SBP and urinary protein excretion (UPE) were significantly lowered with clofibrate treatment. Kidneys from vehicle-treated SHRSP, which were on HS intake for 3 weeks, demonstrated focal lesions of vascular fibrinoid degeneration, which were markedly attenuated with clofibrate treatment. In contrast, 2 weeks of treatment with the selective epoxygenase inhibitor, MS-PPOH, increased UPE without significantly altering neither urinary EET levels nor SBP. Kidneys from vehicle-treated SHRSP, which were on HS intake for 11 days, demonstrated occasional mild damage whereas kidneys from MS-PPOH-treated rats exhibited widespread malignant nephrosclerosis. These results suggest that pharmacological manipulation of epoxygenase results in divergent effects on renal damage and that interventions to increase EET levels may provide therapeutic strategies for treating salt-sensitive hypertension and renal damage.",
keywords = "Clofibrate, Epoxyeicosatrienoic acids, Epoxygenase inhibition, High-salt intake, Proteinuria, Renal damage, SHRSP",
author = "Jing Li and Stier, {Charles T.} and Chander, {Praveen N.} and Manthati, {Vijay L.} and Falck, {J R} and Carroll, {Mair{\'e}ad A.}",
year = "2014",
doi = "10.3389/fphar.2014.00187",
language = "English (US)",
volume = "5 AUG",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage

AU - Li, Jing

AU - Stier, Charles T.

AU - Chander, Praveen N.

AU - Manthati, Vijay L.

AU - Falck, J R

AU - Carroll, Mairéad A.

PY - 2014

Y1 - 2014

N2 - Kidney damage is markedly accelerated by high-salt (HS) intake in stroke-prone spontaneously hypertensive rats (SHRSP). Epoxyeicosatrienoic acids (EETs) are epoxygenase products of arachidonic acid which possess vasodepressor, natriuretic, and anti-inflammatory activities. We examined whether up-regulation (clofibrate) or inhibition [N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH)] of epoxygenase would alter systolic blood pressure (SBP) and/or renal pathology in SHRSP on HS intake (1% NaCl drinking solution). Three weeks of treatment with clofibrate induced renal cortical protein expression of CYP2C23 and increased urinary excretion of EETs compared with vehicle-treated SHRSP. SBP and urinary protein excretion (UPE) were significantly lowered with clofibrate treatment. Kidneys from vehicle-treated SHRSP, which were on HS intake for 3 weeks, demonstrated focal lesions of vascular fibrinoid degeneration, which were markedly attenuated with clofibrate treatment. In contrast, 2 weeks of treatment with the selective epoxygenase inhibitor, MS-PPOH, increased UPE without significantly altering neither urinary EET levels nor SBP. Kidneys from vehicle-treated SHRSP, which were on HS intake for 11 days, demonstrated occasional mild damage whereas kidneys from MS-PPOH-treated rats exhibited widespread malignant nephrosclerosis. These results suggest that pharmacological manipulation of epoxygenase results in divergent effects on renal damage and that interventions to increase EET levels may provide therapeutic strategies for treating salt-sensitive hypertension and renal damage.

AB - Kidney damage is markedly accelerated by high-salt (HS) intake in stroke-prone spontaneously hypertensive rats (SHRSP). Epoxyeicosatrienoic acids (EETs) are epoxygenase products of arachidonic acid which possess vasodepressor, natriuretic, and anti-inflammatory activities. We examined whether up-regulation (clofibrate) or inhibition [N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH)] of epoxygenase would alter systolic blood pressure (SBP) and/or renal pathology in SHRSP on HS intake (1% NaCl drinking solution). Three weeks of treatment with clofibrate induced renal cortical protein expression of CYP2C23 and increased urinary excretion of EETs compared with vehicle-treated SHRSP. SBP and urinary protein excretion (UPE) were significantly lowered with clofibrate treatment. Kidneys from vehicle-treated SHRSP, which were on HS intake for 3 weeks, demonstrated focal lesions of vascular fibrinoid degeneration, which were markedly attenuated with clofibrate treatment. In contrast, 2 weeks of treatment with the selective epoxygenase inhibitor, MS-PPOH, increased UPE without significantly altering neither urinary EET levels nor SBP. Kidneys from vehicle-treated SHRSP, which were on HS intake for 11 days, demonstrated occasional mild damage whereas kidneys from MS-PPOH-treated rats exhibited widespread malignant nephrosclerosis. These results suggest that pharmacological manipulation of epoxygenase results in divergent effects on renal damage and that interventions to increase EET levels may provide therapeutic strategies for treating salt-sensitive hypertension and renal damage.

KW - Clofibrate

KW - Epoxyeicosatrienoic acids

KW - Epoxygenase inhibition

KW - High-salt intake

KW - Proteinuria

KW - Renal damage

KW - SHRSP

UR - http://www.scopus.com/inward/record.url?scp=84906238226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906238226&partnerID=8YFLogxK

U2 - 10.3389/fphar.2014.00187

DO - 10.3389/fphar.2014.00187

M3 - Article

C2 - 25177296

AN - SCOPUS:84906238226

VL - 5 AUG

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 187

ER -